Health

Value-based Health Assessment in Italy: A decentralised model

July 07, 2015

Europe

July 07, 2015

Europe
Martin Koehring

Senior Manager for Sustainability, Climate Change and Natural Resources & Head of the World Ocean Initiative

Martin Koehring is senior manager for sustainability, climate change and natural resources at (part of The Economist Group). He leads Economist Impact's sustainability-related policy and thought leadership projects in the EMEA region. He is also the head of the, inspiring bold thinking, new partnerships and the most effective action to build a sustainable ocean economy.

He is a member of the Advisory Committee for the UN Environment Programme’s Global Environment Outlook for Business and is a faculty member in the Food & Sustainability Certificate Program provided by the European Institute for Innovation and Sustainability.

His previous roles at The Economist Group, where he has been since 2011, include managing editor, global health lead and Europe editor at The Economist Intelligence Unit.

He earned a bachelor of economic and social studies in international relations from Aberystwyth University and a master’s degree in diplomacy and international relations from the College of Europe.

Contact

A decentralised model

Report Summary

Italy is an intriguing case study of how value-based healthcare, which looks at health outcomes of treatment relative to cost, can evolve. The country offers an interesting dichotomy between a pioneering approach to financing innovative treatments on the one hand, and a more complex and arguably less sophisticated institutional structure and measures for assessing healthcare outcomes on the other.

The structure of Italy’s system for health technology assessment (HTA) reflects both its origins as a way of containing rising healthcare costs and the country’s strong economic differences between the north and the south. The uneven organisation of HTA structures at the national and the regional level contrasts with the country’s leadership role in the area of financing innovative therapies, in which consultative and assessment structures are more varied and better established than in many other European countries.

Further reading:

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week